Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Timothy Hobday (NPI 1316919962)

Field	Value
Entity Type	Individual
Organization	Timothy Hobday
Address	200 1st St Sw
City	Rochester
State	MN
ZIP	55905
Taxonomy	Medical Oncology Physician
NPI Enumerated	February 7, 2006

Payer Source	Total Paid
Medicare	$931.3K
Medicaid	$0

Key Findings

This provider is a medical oncology physician in Rochester, MN with a long Medicare tenure—their NPI was enumerated on 2006-02-07 (≈20 years ago), indicating roughly two decades of participation in Medicare billing and likely sustained oncology practice in the market. The longevity supports experience in administering complex cancer therapies and in managing outpatient infusion services.

Medicare is effectively the sole public payer for this provider: total Medicare revenue is $931.3K while there is no Medicaid billing on file, so the provider operates as a single-payer (Medicare-dominated) public-billing profile rather than a dual-payer practice. This concentration means analyses of public-reimbursement risk and utilization should focus on Medicare patterns.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 85.5% of the provider’s total Medicare revenue. Those three codes (J9271, J9144, J9299) are biologic/oncology drug administrations—pembrolizumab, daratumumab, and nivolumab—indicating that a large majority of Medicare revenue is driven by high-cost immunotherapy and monoclonal antibody treatments rather than office visits or non-drug services.

The code mix and service-line implications point to a drug-centric oncology infusion practice: the largest single-code revenue is J9271 (pembrolizumab) at $421.2K, followed by J9144 (daratumumab) at $246.3K and J9299 (nivolumab) at $129.6K. The presence of multiple high-volume injectable biologic codes plus chemotherapy administration/add-on codes (96413, 96417, 96415) and infusion technique codes (G0498) suggests the provider’s operation is oriented around outpatient infusions of targeted and immune therapies rather than visit-based outpatient-only management.

Competitive standing is modest to typical for most high-revenue drugs: J9271 ranks #1079 of 1841 providers nationally (41th percentile) and J9144 ranks #398 of 615 (35th percentile), both characterized in the source as typical, unremarkable volumes for those codes. J9299 ranks low nationally (#476 of 505, 5th percentile) despite contributing materially to revenue, which suggests this provider is not a regional or national leader in nivolumab administration but rather a mid-to-lower volume participant for many of these oncology drug codes.

Some service-level utilization is routine rather than visit-heavy: professional E/M codes such as 99215 (82 claims, $11.2K revenue) and 99214 (22 claims, $2.2K revenue) contribute only small shares of revenue relative to drug codes, reinforcing the interpretation that drug administration—rather than high-volume office E/M—is the primary revenue driver. Ancillary chemotherapy administration codes (96413: $22.2K) exist but are smaller contributors compared with the biologics.

The provider’s per-claim payment profile shows relatively low average paid/claim for several commonly used drugs (for example, J9271 avg $39/claim, J9144 avg $38/claim, J9299 avg $24/claim). Combined with the claim volumes (10.8K, 6.5K, 5.4K respectively), this pattern indicates revenue is being driven by large numbers of low-dollar units consistent with per-mg billing for biologic agents rather than fewer, large bundled payments. Monitor coding units and infusion dosing patterns when comparing peer practices.

Although the practice handles infusion of high-cost agents, its national rank percentiles for these drugs are generally in the mid-to-lower ranges (many codes labeled as "typical, unremarkable volume"). This implies the provider is an established local oncology infusion source with experienced tenure but not a dominant national outlier; strategic considerations should focus on local market share and physician capacity rather than expecting national leadership in these drug administrations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

42 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,800	$40	$421.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,480	$40	$246.3K
J9299	Injection, nivolumab, 1 mg	5,400	$20	$129.6K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	2,700	$10	$24.3K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,020	$20	$22.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	210	$110	$22.2K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	170	$70	$12.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	80	$140	$11.2K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	70	$130	$8.6K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	20	$210	$5.1K

Showing 1–10 of 42

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 42 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Timothy Hobday — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

42 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	70	7,200	$40	$323.3K
J9144	5	50	3,780	$40	$163.7K
J9299	10	20	5,240	$20	$159.4K
J2506	13	20	290	$80	$34.3K
Q5119	22	30	1,380	$20	$29.5K
J9264	6	10	2,760	$10	$27.1K
J9217	58	80	80	$130	$17.1K
96413	44	230	70	$100	$11.5K
99214	8,579	10,100	70	$80	$8.1K
99215	665	4,060	30	$120	$5.9K

Showing 1–10 of 42

Related Providers

Other providers that share a Tax Identification Number (TIN) with Timothy Hobday, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$74.3M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic Health System-southeast Minnesota Region	MN	Multi-Specialty Clinic/Center	$0	$13.7M
Mayo Clinic Hospital-rochester	MN	General Acute Care Hospital	$0	$11.5M
Robert Jacobson	MN	Pediatrics Physician	$975.6K	$0
Mojun Zhu	AZ	Hematology & Oncology Physician	$947.4K	$0
Lionel Aurelien Kankeu Fonkoua	MN	Medical Oncology Physician	$899.8K	$0
Matthew Block	MN	Medical Oncology Physician	$820.5K	$0
Ron Smith	MN	Radiation Oncology Physician	$806K	$0
Julian Molina	MN	Medical Oncology Physician	$773.4K	$0

Nearby Providers

Other providers in the same ZIP code as Timothy Hobday, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$10.9M
Mayo Foundation For Medical Education & Research	MN	Durable Medical Equipment & Medical Supplies	$9.3K	$2.8M
Vidhu Kaushik	MN	Clinical Pathology/Laboratory Medicine Physician	$59.6K	$1.9M
Roberto Leon Ferre	MN	Medical Oncology Physician	$1.3M	$0
Peter Noseworthy	MN	Cardiovascular Disease Physician	$1.1M	$0
Daniel Childs	MN	Medical Oncology Physician	$1.1M	$0
Brittany Siontis	MN	Medical Oncology Physician	$960.6K	$0
Sani Kizilbash	MN	Medical Oncology Physician	$946.7K	$0
Katharine Price	MN	Medical Oncology Physician	$832.6K	$0

Timothy Hobday — Billing Profile & Reimbursement Data

Sign up for Timothy Hobday — Billing Profile & Reimbursement Data policy alerts

Timothy Hobday — Billing Profile & Reimbursement Data

Sign up for Timothy Hobday — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References